India

Supreme Court Pushes for Pharma Marketing Regulation

By admin
13 min read


This has been one of the worst kept secrets, unknown to the public yet largely known to the medical community and pharma sector for years. Sponsored foreign trips for conferences, or junkets, often including family members, and outright gifting are among the inducements offered to doctors as part of Big Pharma’s marketing practices. Doctors ruled by their conscience reject such overtures outright. Yet, such practices are known to be widely prevalent due to the absence of a statutory regulatory regime. But when the highest court of the land takes cognizance, it raises hope that this long-unaddressed issue may finally be addressed.

On October 8, a Supreme Court Bench,acting on a 2021 writ petition, directed the Union government to constitute a committee to recommend a framework of legal safeguards to monitor and control unethical pharma marketing practices. On October 22, the Department of Pharmaceuticals (DoP) set up a committee to “conduct a comprehensive examination of the effectiveness of the existing frameworks governing pharmaceutical marketing practices and to formulate appropriate recommendations for strengthening the oversight mechanisms”. This three-member committee is chaired by a NITI Aayog member, M. Srinivas. The other members are Preeti Sudan, former Union Health Secretary, and Naresh Trehan, managing director, Medanta, a private hospital network.

The committee has a six-point terms of reference framework: undertake a holistic and comprehensive examination of all issues relating to unethical pharmaceutical marketing practices; examine the efficacy of the existing mechanisms for monitoring, oversight, and enforcement with respect to unethical pharma marketing practices and identify measures required to ensure greater transparency, accountability, and effective compliance; assess the need for measures required to strengthen the existing monitoring and regulatory framework and suggest appropriate regulatory/statutory or other measures and legal framework for implementation of such measures as necessary; discuss with stakeholders concerned, technical, professional, domain experts, institutions or bodies as considered necessary and consider their submissions objectively while submitting recommendations on the matter after a comprehensive examination; recommend and deliberate any other relevant issue in connection with curbing unethical pharma marketing practices; and submit its report within two months from the date of its first meeting.

The composition of the committee and its terms of reference were not acceptable to the petitioners. On October 26, one of the petitioners and two public health advocacy organisations, Jan Swasthya Abhiyan (India) and Swasthya Adhikar Manch, wrote to the Secretary, DoP, demanding an inclusive, independent, and conflict-free committee. They asserted that the committee’s present composition would not facilitate achieving its stated objective of addressing unethical pharmaceutical practices and ensuring accountability. “A committee dealing with such an important public health issue must be constituted with independent experts with adequate safeguards against conflicts of interest,” stated the letter.

On behalf of Jan Swasthya Abhiyan (India), Amitava Guha, who was one of the petitioners in the Supreme Court case (FMRAI & Others v. Union on India & Others), and Amulya Nidhi of Jan Swasthya Abhiyaan (JSA India)questioned, in the October 26 letter,the terms of reference of the committee and the nature of its composition.

The legal struggle

In 2021, the Federation of Medical and Sales Representatives Association of India (FMRAI), along with other petitioners, approached the Supreme Court to direct the government to come up with a regulatory framework with legislative backing to regulate unethical marketing practices by pharma companies. This was after several efforts to get the government to enact a statutory body failed.

Also Read | High drug prices are giving counterfeiters a booster shot

It was way back in 2005 that the FMRAI, a national body set up in 1963 under the Trade Unions Act, started writing to the Central government to set up a regulatory body with legally enforceable penal provisions to control unethical pharma marketing practices. The Jan Swasthya Abhiyan, a broad platform of public health activists, joined those efforts. The government did nothing.

A poster at a pharmacy in Hyderabad urges customers to always carry their prescription when buying medicines, a file photograph. But with big pharma marketing practices subject to self-regulation by the stakeholder companies, without any statutory checks, can a prescription be relied upon to necessarily give the right advice?

A poster at a pharmacy in Hyderabad urges customers to always carry their prescription when buying medicines, a file photograph. But with big pharma marketing practices subject to self-regulation by the stakeholder companies, without any statutory checks, can a prescription be relied upon to necessarily give the right advice?
| Photo Credit:
MOHAMMED YOUSUF

The 2021petition highlighted the alleged prevalence of unethical marketing and promotional practices of pharmaceutical companies in their dealings with healthcare professionals. It was pointed out that these practices could potentially lead to irrational prescription, including prescription of combination drugs in excess of their therapeutic requirements, and encourage a preference for overpriced branded drugs, imposing a huge financial burden on patients.

The petitioners contended that such practices also led to adverse drug reactions and emergence of antimicrobial and antibiotic resistance.

There were statutory ethical restrictions governing medical professionals in their relationship with pharmaceutical companies under the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations 2002. But there was no corresponding statutory regulation governing the pharma sector for offering inducements.

UCPMP: Voluntary, and therefore ineffective

In a half-hearted measure in 2015, the Union government introduced the Uniform Code for Pharmaceuticals Manufacturing Practices (UCPMP), a voluntary, industry-led self-regulatory mechanism to promote ethical pharmaceutical marketing practices and regulate interactions between pharmaceutical companies and medical professionals. Its purported purpose was to ensure that the promotion of pharmaceutical products was accurate, balanced, and evidence-based, and that prescribing and treatment decisions were not improperly influenced by gifts, financial inducements, or other benefits. The UCPMP proved ineffective because it was voluntary.

In 2024, the DoP (which is under the Ministry of Chemicals and Fertilizers) introduced a slightly tweaked UCPMP superseding the 2015 code, apparently in order to strengthen its implementation. The code was in the form of compulsory guidelines but still lacked statutory backing.

In September 2026, when the 2021 writ was being heard in court, the government told the court it had submitted an affidavit stating it intended to constitute a three-member committee to examine the issues in the present proceedings and to make recommendations for an appropriate regulatory and statutory framework to address the concerns raised in the petition. It also stated that until the time that the recommendations were considered and acted upon by the government, the 2024 UCPMP would be in force.

This was not acceptable to the petitioners, who pointed out that committees were set up earlier as well. In September 2022, the government constituted a High Level Group chaired by a NITI Aayog member. This committee recommended strengthening the existing framework but did not recommend a statutory status for the UCPMP.

The petitioners said in the October 26 letter that a committee set up to monitor marketing practices in pharma should ensure that a conflict of interest does not undermine independent oversight, public accountability, or the interests of patients and the general public. The committee, they said, should include independent experts and individuals with demonstrable experience in addressing unethical pharma marketing, drug-related issues, unethical clinical trials, pharma industry irregularities, and violation of medical ethics.

Such a committee, they said, should also include organisations working on public health, pharmacology, medical ethics, health rights, access to affordable medicines, and accountability in the pharmaceutical sector. It should include independent medical and public health experts, civil society organisations, and other stakeholders who would bring evidence-based perspectives, and represent public interest.

A bottle of Coldrif cough syrup and a prescription that a young mother  received from a doctor for her six-month-old son in Parasia, Madhya Pradesh, in October 2025. The syrup was later banned after it was linked to the deaths of multiple children.

A bottle of Coldrif cough syrup and a prescription that a young mother received from a doctor for her six-month-old son in Parasia, Madhya Pradesh, in October 2025. The syrup was later banned after it was linked to the deaths of multiple children.
| Photo Credit:
PRIYANSHU SINGH/REUTERS

The letter to the DoP emphasised, without naming anyone, that no persons from the healthcare industry should be included in the committee. As the court case itself was against the government, it was urged that the presence of former or present government officials should be “avoided” in the committee. “As our issue is with the government, it is odd to constitute a committee with people who had served in government,” Amitava Guha told Frontline.

The department was requested to reconstitute the committee on the lines urged by the petitioners. In November, the petitioners filed an application in court reiterating their reservations on the composition of the three-member committee, which they said “does not give effect to the concerns raised by the petitioners and to the letter and spirit of the directions” of the court.

The 2022 high-level committee never gave a copy of its recommendations to the petitioners. The application referred to a counter affidavit by the government, submitted during the hearings this year, which stated that the 2022 committee had concluded that the UCPMP need not be made statutory. The committee had recommended strengthening the existing framework through greater transparency, independent scrutiny, complaint-monitoring, IT-enabled disclosures, and alignment with National Medical Commission regulations.

The UCPMP 2024 was pursuant to the recommendations of the 2022 committee. Fundamentally, it was not very different from the 2015 code.

The petitioners were of the opinion that since a previous committee chaired by a NITI Aayog member had already given its opinion on the matter, which was quoted in the government’s affidavit, constituting another committee headed by a NITI Aayog member was pointless. The November application sought a court order setting aside the government’s October 22 order announcing the composition of the committee. It sought a direction to the government for reconstituting the committee in accordance with the October 8 court order.

In the October 8 order, the Bench observed that the material placed before it indicated that “the existing framework has not proved entirely effective in preventing and curbing unethical practices in the pharmaceutical sector. The concerns brought to our notice are of considerable significance.”

The order further noted that “in a sector which has a direct bearing on the health and well-being of citizens, the efficacy of the regulatory framework cannot be assessed merely by the existence of prescribed norms; it must also be judged by their efficacy, implementation and enforcement”. The order called for a “careful examination of the measures required to strengthen the existing regulatory mechanism so as to ensure that such practices are effectively checked and do not gain further ground, while safeguarding the larger public interest in ensuring the availability of ethical, accessible and affordable healthcare services”.

It said that the Union government had agreed to constitute a committee to look into the issue and make recommendations “regarding an appropriate statutory and regulatory framework for regulating the conduct of pharmaceutical companies, particularly with a view to ensuring that pharmaceutical companies do not indulge in unethical practices in their dealings with medical practitioners”. The constitution of such a committee, the order noted, reflected the need for a closer examination of the existing framework and the measures required to strengthen it.

Emphasis on ‘larger public interest’

While the judgment made observations on protecting the “legitimate interests” of pharmaceutical companies, it notably emphasised the need for “ethical, affordable, accessible healthcare” in the public interest. The efficacy of any regulatory framework, it noted, depended not only on prescribed standards and obligations but also on mechanisms for implementation, monitoring, transparency, and accountability.

The court, while acknowledging that the formulation of any regulatory policy lay within the domain of the government, noted that the judiciary was “required to ensure that the regulatory framework ultimately adopted is consistent with the constitutional guarantees and in larger public interest”. Exercising judicial restraint did not imply that the court could remain indifferent when the material laid before it disclosed concerns that had a direct bearing on public health and the right to health.

The court directed the government to constitute a committee whose purpose would be to undertake a holistic and comprehensive examination of all issues relating to unethical pharmaceutical marketing practices.

Required: Compliance affidavit

That the court meant business was evident in several of its directions, especially those to the government. The operative term was “larger public interest”, which appeared several times in the order. The committee was directed to adopt a consultative process, involving relevant stakeholders. The recommendations of the committee would be submitted to the government, which would be expected to take an appropriate decision at the earliest.

The government was also directed to file a compliance affidavit in court detailing the constitution of the committee, its first meeting, the manner in which the consultative process was undertaken, and the progress made towards the completion of the exercise. The affidavit would also include the committee’s recommendations, the government’s decision on them, as well as measures proposed for strengthening the regulatory framework governing pharmaceutical marketing practices. The compliance affidavit, the order held, was to be filed within two weeks of the completion of the committee’s own exercise.

A woman displays her empty purse after paying her medical bills. Out-of-pocket expenditure on healthcare is high in India. Unethical marketing practices of big pharma can potentially lead to irrational prescriptions and push up medical costs. The image here is representative.

A woman displays her empty purse after paying her medical bills. Out-of-pocket expenditure on healthcare is high in India. Unethical marketing practices of big pharma can potentially lead to irrational prescriptions and push up medical costs. The image here is representative.
| Photo Credit:
GETTY IMAGES

Clearly, the court was keen on time-bound and effective resolution of an issue that had hung fire for decades The next hearing of the petition will be held on January 29, 2027. The committee’s recommendations, the government’s follow-up action, and a compliance affidavit by the government will have to be submitted by that time.

Also Read | What kept cancer medication unaffordable for so long?

As per available information, only one instance has come to light where the DoP, on December 23, 2024, following an anonymous complaint, issued an order to the Indian arm of an American drug major for violating UCPMP guidelines. The company had allegedly sponsored extravagant pleasure trips of 30 healthcare professionals to overseas destinations under the pretext of holding conferences. The company denied any wrongdoing. The ethics committee of a leading pharma producer organisation also did not find anything amiss.

But the Apex Committee of Pharma Marketing Practices under the DoP thought otherwise. Its audit committee concluded the company had violated the UCPMP. The company was offered a chance to redeem itself by providing support to underprivileged patients in government hospitals for an amount equivalent to the violations computed by the audit team. The company refused. The matter ended with a reprimand to the company and a request to the Central Board of Direct Taxes to evaluate the tax liability of the company and the medical professionals concerned, and the National Medical Commission was requested to take action against the medicos involved. No legal proceedings could be initiated against the pharma company because it had not violated any law.

As of now, the only supporters of the UCPMP in its present non-statutory form are pharma producer associations and the Union government. A statutory regulation of unethical pharma marketing practices is not a big ask. It should not be a challenge for any government to enact a law, given that the ramifications of unethical pharma marketing practices lie beyond the very act itself, influencing affordable and quality healthcare.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Saved Articles